 WARMER, Pa., July 21, 2022 GLOBE NEWSWIRE -- Arbutus Biopharma Corporation Nasdaq: ABUS, a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2022 financial results and corporate update for Thursday, August 4, 2022. The schedule for the press release and conference callwebcast are as follows: 